Biote CorpBTMD
BTMD
About: Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
Employees: 194
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 8
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
11% more funds holding
Funds holding: 75 [Q2] → 83 (+8) [Q3]
0.72% more ownership
Funds ownership: 54.07% [Q2] → 54.79% (+0.72%) [Q3]
19% less capital invested
Capital invested by funds: $122M [Q2] → $99.6M (-$22.9M) [Q3]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q2] → 2 (-1) [Q3]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
97%
upside
Avg. target
$12
97%
upside
High target
$12
97%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Craig-Hallum Alex Fuhrman 38% 1-year accuracy 3 / 8 met price target | 97%upside $12 | Buy Initiated | 16 Dec 2024 |
Financial journalist opinion
Based on 5 articles about BTMD published over the past 30 days
Positive
Zacks Investment Research
2 days ago
Is biote Corp. (BTMD) Stock Outpacing Its Medical Peers This Year?
Here is how biote Corp. (BTMD) and Doximity (DOCS) have performed compared to their sector so far this year.
Positive
Zacks Investment Research
4 days ago
Should Value Investors Buy biote Corp. (BTMD) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Positive
Zacks Investment Research
2 weeks ago
Does biote Corp. (BTMD) Have the Potential to Rally 43.89% as Wall Street Analysts Expect?
The mean of analysts' price targets for biote Corp. (BTMD) points to a 43.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Positive
Zacks Investment Research
3 weeks ago
Are Investors Undervaluing biote Corp. (BTMD) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Zacks Investment Research
4 weeks ago
biote Corp. (BTMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for biote Corp. (BTMD), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Predict a 76.99% Upside in biote Corp. (BTMD): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 77% in biote Corp. (BTMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
Zacks Investment Research
1 month ago
Is biote Corp. (BTMD) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Neutral
Seeking Alpha
1 month ago
biote Corp. (BTMD) Q3 2024 Earnings Call Transcript
biote Corp. (NASDAQ:BTMD ) Q3 2024 Earnings Call November 12, 2024 5:00 PM ET Company Participants Szymon Serowiecki - Investor Relations Terry Weber - Chief Executive Officer Bob Peterson - Chief Financial Officer Conference Call Participants Jonna Kim - Cowen Jeff Van Sinderen - B. Riley Kaumil Gajrawala - Jefferies Les Sulewski - Truist Securities George Kelly - ROTH Capital Partners Operator Welcome to the biote Third Quarter 2024 Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Biote Corp. (BTMD) Beats Q3 Earnings Estimates
Biote Corp. (BTMD) came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to loss of $0.11 per share a year ago.
Neutral
Business Wire
1 month ago
Biote Reports Third Quarter 2024 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 m.
Charts implemented using Lightweight Charts™